Olenasufligene relduparvovec

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Olenasufligene relduparvovec
DrugBank Accession Number
DB16264
Background

Olenasufligene relduparvovec is under investigation in clinical trial NCT03612869 (Study of aavrh10-h.sgsh Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)). It is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.1

Type
Biotech
Groups
Investigational
Biologic Classification
Gene Therapies
Other gene therapies
Synonyms
  • AAVrh10-h.SGSH
  • Aavrh10-hsgsh
  • Dna (recombinant adeno-associated virus 2 vector lys-saf302 human n-sulfoglucosamine sulfohydrolase cdna-specifying)
  • LYS-SAF302
  • Olenasufligene relduparvovec
External IDs
  • LYS-SAF-302
  • LYS-SAF302
  • SRP-9002

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7DU50HR4GB
CAS number
2096510-84-6

References

General References
  1. BioSpace: Lysogene Becomes Latest Company to Fail with AAVs in CNS Disorders (Updated) [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3Active Not RecruitingTreatmentMucopolysaccharidosis IIIA1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 18:17 / Updated at June 02, 2023 02:07